Animal gastric cancer in-situ primary model construction method

By injecting experimental plasmids and SB transposase plasmids into the gastric mucosal walls, a primary model of gastric cancer in situ was constructed, which solved the shortcomings of existing models in biological differences and microenvironment reconstruction, and achieved an efficient and controllable gastric cancer model. Preparation enhances the relevance of research and clinical applications.

CN119040394APending Publication Date: 2024-11-29THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411093436.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing gastric cancer model cannot fully simulate the pathogenesis of human gastric cancer. There are biological differences, insufficient reconstruction of complex microenvironment, poor reproducibility and comparability of results, and limited drug response prediction capabilities, which limit the effectiveness of the study and clinical application.

Method used

The mixed solution of experimental plasmid and SB transposase plasmid is used to inject it into the animal gastric mucosa wall to construct an in situ primary model of animal gastric cancer, simulate the transformation process of gastric mucosal cells into tumor cells in human body, dynamically characterize the tumor occurrence and development, and in the short term Efficient preparation of gastric cancer models that meet clinical characteristics within time.

Benefits of technology

This method shortens the model construction cycle, improves the tumor growth rate, can be closer to the tumor microenvironment in the human body, provides a gastric cancer model closer to the needs of clinical research, and enhances the ability to study the mechanism of gastric cancer occurrence and development and explore new treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040394A_ABST
    Figure CN119040394A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of animal tumor models, and particularly discloses a construction method of an animal gastric cancer in-situ primary model, which comprises the following steps: mixing experimental plasmids and SB transposase plasmids to obtain a mixture, taking the mixture as a solute, taking normal saline as a solvent, and injecting the solute into the gastric mucosa wall of an animal. The invention also discloses an animal gastric cancer in-situ primary model which is obtained by adopting the construction method. The construction period of the model is obviously shortened compared with that of a genetic engineering animal model, animal death before tumor formation cannot be caused, and the tumor formation rate is high. The in-situ primary mouse stomach tumor model constructed by the invention can simulate the process of transforming normal gastric mucosa cells into tumor cells in a human body, can dynamically represent the tumor generation and development process, and is closer to the real tumor generation and development situation in the tumor microenvironment, tumor development, pathophysiology and other processes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of animal tumor models, and in particular to a method for constructing an in situ primary model of animal gastric cancer. Background Art

[0002] Gastric cancer is still a major cancer worldwide. According to the "Global Cancer Statistics", there were more than 1.5 million new cases of gastric cancer and about 900,000 deaths worldwide last year. The incidence and mortality rates ranked second and third in the world, and East Asia, including China, has become the region with the most serious incidence in the world.

[0003] Traditional treatments for gastric cancer include surgery, chemotherapy, and radiotherapy. 50% of surgically treated patients will relapse, and the 5-year recurrence-free survival rate for advanced gastric cancer is only 20%. Clinically, immunotherapy and targeted therapy are newly developed effective treatments for advanced and late-stage gastric cancer. However, as the tumor progresses, the treatment effect also decreases.

[0004] Therefore, studying the occurrence and development mechanism of gastric cancer has always been the focus of basic research on gastric cancer. At present, in-depth exploration and deciphering of gastric cancer-specific molecular targets and related tumor-promoting mechanisms is an important direction in the field of basic research.

[0005] Existing gastric cancer models are mainly divided into primary tumor models and transplanted tumor models. However, there is still no gastric cancer model that can fully explain the pathogenesis of gastric cancer, and each gastric cancer model has certain limitations. Therefore, it is still necessary to explore new and different gastric cancer models so that researchers can choose the appropriate gastric cancer model to solve specific scientific problems.

[0006] Transplanted tumor model: According to the transplantation site, it can be divided into subcutaneous transplantation and orthotopic transplantation; according to the tumor species, it can be divided into mouse transplanted tumor model and human transplanted tumor model. Currently, the types of mouse tumor cell lines that can be used for transplantation are very limited. Human transplanted tumor models can be divided into PDX models (gastric cancer tissue blocks from patients are inoculated into immunodeficient mice) and CDX models (human gastric cancer cell lines are inoculated into immunodeficient mice). However, the following defects still exist:

[0007] (1) The mouse gastric cancer transplant model is established by transplanting human gastric cancer cells into mice. Although it can simulate the growth process of human gastric cancer, there are still some differences because the biological characteristics and metabolic mechanisms between mice and humans are not exactly the same.

[0008] (2) The development of gastric cancer is affected by surrounding tissues, including vascular supply, immune cell infiltration, etc. However, the mouse gastric cancer transplant model cannot fully reproduce these complex microenvironments and can only provide limited information.

[0009] (3) There are certain differences in the mouse gastric cancer transplant tumor model between different laboratories. Due to differences in operating techniques, mouse strains, and cell sources, there are certain problems with the reproducibility and comparability of the results.

[0010] (4) Limited ability to predict drug response. Mouse gastric cancer xenograft models are often used to evaluate the efficacy of new drugs. However, due to the limitations and complexity of the model, its ability to predict drug response is limited, which may lead to discrepancies between preclinical research results and actual clinical effects.

[0011] Gastric cancer primary tumor model: It can be divided into induced gastric cancer model and genetically engineered mouse gastric cancer model. The induced gastric cancer model uses chemical carcinogenesis and Helicobacter pylori infection to induce cancer in the stomach of inbred mice; the chemical carcinogenesis method mainly uses N-methyl-N-nitrosourea (MNU). The genetically engineered mouse gastric cancer model has become popular. This type of model directly edits the genes related to gastric cancer occurrence. The morphological characteristics of the tumors formed are very similar to the natural occurrence of human tumors, and the specificity is very high. It has unique advantages in studying the occurrence and development mechanism of gastric cancer (especially signal pathway research); including Tff1 knockout mice, INS-GAS transgenic mice, Gp130 mutant mice, H / K-ATPase:IL-1β transgenic mice and K-Ras transgenic mice.

[0012] Although the gastric cancer primary tumor model can provide some information about the development of gastric cancer, it also has some shortcomings, including the following: (1) Long time: It usually takes a long time to establish a mouse gastric cancer primary tumor model, which may take months or even longer to form an observable tumor. This requires researchers to invest more time and resources and may limit the progress of experiments and the acquisition of rapid results. (2) Difficulty in controlling tumor properties: During the process of inducing gastric cancer formation in mice, the growth and development of tumors are often random and unpredictable. Therefore, it may be challenging to obtain consistent and comparable tumor properties in the model, which may have a certain impact on the interpretation of data and the consistency of results. (3) Lack of microenvironment: Similar to the transplant tumor model, the gastric cancer primary tumor model is also difficult to fully reproduce the complex microenvironment in the human body. Factors such as cell interactions, vascular supply, and immune cell infiltration in the microenvironment have an important impact on tumor development and treatment response, and these aspects are difficult to accurately simulate in mouse models. (4) Inability to fully represent human diseases. There are biological and genetic differences between mice and humans, which leads to the inability of mouse gastric cancer primary tumor models to fully represent the complexity and diversity of human diseases. Therefore, the results and insights obtained from the model may sometimes not be directly applicable to human clinical practice.

[0013] In general, although the existing mouse gastric cancer modeling methods have certain application value in the field of gastric cancer research, they also have some limitations and shortcomings. When designing experiments and interpreting data, it is often necessary to fully consider these limitations and combine them with other research methods and models to obtain more comprehensive and accurate conclusions. Summary of the invention

[0014] The purpose of the present invention is to solve the shortcomings of the prior art and to propose a method for constructing an in situ primary model of animal gastric cancer.

[0015] A method for constructing an in situ primary model of gastric cancer in animals comprises the following steps: using a mixture of an experimental plasmid and an SB transposase plasmid as a solute, using physiological saline as a solvent, and injecting the mixture into the gastric mucosal wall of the animal.

[0016] Preferably, the experimental plasmids include: AKT plasmid and NICD1 plasmid.

[0017] Preferably, gastric cancer is gastric adenocarcinoma.

[0018] Preferably, the animal is a mouse.

[0019] Preferably, the concentrations of the AKT plasmid, the NICD1 plasmid and the SB transposase plasmid in the injection system are all 2.5 μg / mL.

[0020] Preferably, the gastric mucosal wall is the gastric mucosal wall on the lesser curvature of the stomach.

[0021] Preferably, the specific operation of injecting into the gastric mucosal wall of the animal is as follows: after the animal is anesthetized, the stomach is pulled out of the abdomen, and physiological saline containing the experimental plasmid and SB transposase plasmid is pushed into the gastric mucosal wall, and then the stomach is placed back into the abdominal cavity and the abdominal incision is closed.

[0022] An in situ primary model of animal gastric cancer is constructed by using the above-mentioned method for constructing an in situ primary model of animal gastric cancer.

[0023] Preferably, the animal is a mouse.

[0024] Preferably, gastric cancer is gastric adenocarcinoma.

[0025] The model construction cycle of the present invention is significantly shorter than that of the genetic engineering animal model, will not cause the death of animals before tumor formation, and has a high tumor formation rate.

[0026] The in situ primary mouse gastric tumor model constructed by the present invention can simulate the process of transformation of normal gastric mucosal cells into tumor cells in the human body, can dynamically characterize the process of tumor occurrence and development, and is closer to the actual situation of tumor occurrence and development in terms of tumor microenvironment, tumor development and pathophysiology.

[0027] The method of the present invention can efficiently prepare a gastric cancer model that is closer to the characteristics of gastric cancer and meets the needs of clinical research. This model can provide a powerful tool in the research fields of exploring the mechanism of gastric cancer occurrence and development, finding and optimizing new possible treatment methods for gastric cancer, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a photo of using scissors to cut the upper abdominal skin and abdominal wall muscles, finding the stomach through the surgical incision, and carefully pulling the stomach onto the gauze outside the abdomen with toothless forceps.

[0029] Figure 2 This is a photo of the experimental group using an insulin needle to quickly inject the plasmid mixed solution into the gastric mucosal wall on the lesser curvature of the mouse stomach.

[0030] Figure 3 This is the body weight change curve of mice in the experimental group and the control group.

[0031] Figure 4 This is a photo of the stomach tissue of mice in the control group.

[0032] Figure 5 These are photos of stomach tissues of mice in the experimental group.

[0033] Figure 6 HE staining of gastric cancer tissue in mice in the control group.

[0034] Figure 7-9 HE staining of gastric cancer tissue in mice in the experimental group. DETAILED DESCRIPTION

[0035] The present invention will be further explained below in conjunction with specific embodiments.

[0036] Example 1

[0037] AKT plasmid (pT3-myr-AKT-HA), NICD1 plasmid (pT3-EF1a-NICD1) and SB transposase plasmid (Sleeping Beauty transposase plasmid) were amplified respectively.

[0038] The amplification method is the same, and the AKT plasmid is used as an example for explanation. The specific operation is as follows:

[0039] (1) Take out 100 μL of DH5α competent cells from the -80°C refrigerator and thaw on ice;

[0040] (2) Quickly add 2 μL of AKT plasmid solution (containing about 1 μg of plasmid) and shake gently;

[0041] (3) Ice bath for 30 min, while preheating the water bath to 42°C;

[0042] (4) Heat shock the tube in a 42°C water bath for 45-90 seconds. Do not move the tube during the heat shock process.

[0043] (5) Immediately give an ice bath for 3-5 minutes;

[0044] (6) Add 1 mL of non-resistant LB liquid medium to the centrifuge tube, pipette and mix well, and then place in a 37°C shaker at 200 rpm for 1 h. Slight turbidity can be seen (at this time, the bacteria have resumed normal growth and expressed the antibiotic resistance gene in the plasmid);

[0045] (7) Centrifuge at 5000-6000 rpm for 5 min;

[0046] (8) Discard 900 μL of supernatant and keep 100 μL of liquid to resuspend the bacteria;

[0047] (9) Prepare LB solid medium with corresponding antibiotics in advance and preheat it in an incubator at 37°C;

[0048] (10) Inoculate 100 μL of resuspended bacteria onto the preheated solid culture medium and spread evenly with an inoculation loop;

[0049] (11) After inoculation, place the culture dish face up for 30 min. After the bacterial solution is completely absorbed by the culture medium, invert the culture dish and incubate it at 37°C for 12-16 h.

[0050] (12) Use a pipette to pick out the cloned bacteria and inoculate them into 5 mL of LB liquid culture medium containing the corresponding antibiotics;

[0051] (13) Incubate at 37°C in a shaker at 200 rpm / min for 12-16 h until the bacterial solution becomes turbid.

[0052] (14) After centrifugation, plasmid extraction was performed using an endotoxin-free plasmid extraction kit.

[0053] Example 2

[0054] The specific operation of plasmid extraction in step (14) of Example 1 is as follows:

[0055] (1) Transfer the bacterial solution to a 15 mL centrifuge tube and centrifuge for 5 min;

[0056] (2) Pour out the bacterial solution and remove the precipitate by suction;

[0057] (3) Add 250 μL of solution P1 (check whether RNase A has been added), shake it evenly with a shaker and pipette, and transfer it to a sterile 1.5 mL centrifuge tube;

[0058] (4) Add 250 μL of solution P2 to the centrifuge tube and gently invert it upside down 6-8 times to fully lyse the bacteria;

[0059] (5) Add 350 μL of solution P3 to the centrifuge tube, gently invert it upside down 6-8 times, mix thoroughly, and centrifuge it at 13400 g for 10 min. Transfer the supernatant to the filter column CS (do not suck up the precipitate during the transfer of the supernatant);

[0060] (6) Centrifuge the filtrate of the filter column CS at 13400 g for 2 min, and transfer the solution obtained in the collection tube after centrifugation to the adsorption column CP3; add 500 μL of the equilibrium solution BL to the adsorption column CP3, centrifuge at 13400 g for 1 min, discard the waste liquid, and put the adsorption column back into the collection tube;

[0061] (7) Centrifuge at 12000 rpm for 30-60 s, discard the waste liquid, and place the adsorption column CP3 into the collection tube;

[0062] (8) Add 500 μL of deproteinized solution PD to the adsorption column CP3, centrifuge at 13400 g for 60 s, pour out the waste liquid, and place the adsorption column CP3 in a collection tube;

[0063] (9) Add 600 μL of rinse solution PW (with anhydrous ethanol) to the adsorption column CP3, centrifuge at 13400 g for 1 min, discard the waste liquid, and place the adsorption column CP3 in a collection tube;

[0064] (10) Repeat step (9) of this embodiment;

[0065] (11) Centrifugation at 13400 g for 2 min;

[0066] (13) Place the adsorption column CP3 in a clean centrifuge tube, add 100 μL of elution buffer TB to the middle part of the adsorption membrane, leave it at room temperature for 2 min, and collect the plasmid solution in the centrifuge tube;

[0067] (13) Use a nucleic acid quantifier to measure the plasmid concentration.

[0068] Example 3

[0069] Construct an orthotopic primary gastric cancer model. The specific steps are as follows:

[0070] (1) The AKT plasmid, NICD1 plasmid and SB transposase plasmid obtained by amplification and extraction were mixed and added into physiological saline to form a mixed solution (the concentrations of the AKT plasmid, NICD1 plasmid and SB transposase plasmid in the mixed solution system were all 2.5 μg / mL);

[0071] (2) C57 mice (male, weighing 20-25 g / mouse, 6-8 weeks old) were used as test subjects. Food and water were prohibited for 12 hours before surgery. Pentobarbital was dissolved in normal saline at a ratio of 1:100 and injected intraperitoneally at a rate of 7.5 μL / g body weight to anesthetize the mice.

[0072] (3) Fix the mouse with tape, remove the mouse hair with a skin preparation knife, mark the surgical area, and disinfect it three times with iodine cotton balls;

[0073] (4) Use scissors to cut open the upper abdominal skin and abdominal wall muscles, find the stomach through the surgical incision, and use toothless forceps to carefully pull the stomach onto the gauze outside the abdomen. Figure 1 As shown;

[0074] (5) In the experimental group, the mixed solution obtained in step (1) was rapidly injected into the gastric mucosal wall of the lesser curvature of the stomach of the mice using an insulin needle, and attention was paid to whether there was any leakage of the liquid. Figure 2 As shown;

[0075] In the control group, 5% glucose solution was used as the solute (normal saline was used as the solvent, and the glucose concentration was 2.5 μg / mL) and was rapidly injected into the gastric mucosal wall of the lesser curvature of the stomach of mice through an insulin needle.

[0076] (6) After the injection, the stomach was placed back into the abdominal cavity, and the abdominal incision was closed layer by layer using interrupted sutures using 4-0 needles and threads;

[0077] (7) Observe the reaction of the operated mice and allow them to wake up in a warm and suitable environment. After anesthesia is recovered, place the mice back into the cage and allow them to eat and drink freely.

[0078] (8) Observe the weight changes of mice continuously every week;

[0079] (9) After 8 weeks, the operated mice were fasted for 24 h and then anesthetized. The mice were killed and the abdominal cavity was opened again. The appearance of the stomach wall of the experimental mice was observed. The stomach was separated from the esophagus and duodenum, and the stomach was cut open along the greater curvature of the stomach with tissue scissors. The stomach tissue was cleaned with pre-cooled PBS solution. After cleaning, the stomach was placed on a camera and photographed (see Figure 2). Figure 4 and Figure 5 After the shooting, the gastric mucosal lesion area was marked with 4-0 surgical sutures and fixed with formalin; then the slides were sealed with paraffin and stained with HE to observe the gastric mucosal lesions (as shown in Figure 2). Figures 6 to 9 Two or more pathologists were invited to evaluate the gastric mucosa and determine the nature of the gastric mucosal lesions.

[0080] The weight change curves of mice in the experimental group and the control group are shown in Figure 3 As shown, there was no significant difference in body weight between the two groups of mice in the first four weeks, but the mice in the experimental group began to lose weight in the fourth week, suggesting that the mice in the experimental group had lesions in the gastric mucosa.

[0081] Figure 4 and Figure 5 The results showed that the gastric tissue of the mice in the experimental group was larger than that in the control group, suggesting that the mice in the experimental group had lesions in the gastric mucosa.

[0082] Figure 7 , Figure 8 , Fig. 9 All are HE staining of gastric cancer tissues of mice in the experimental group. It can be seen that the gastric mucosa of the mice is disordered, with atypical cells and glands. The glands show complex branches and fusions, and the glandular ducts deep in the mucosa expand and grow laterally; while the atypical cells are cubic, with more obvious structural disorder and more nuclear divisions.

[0083] The Chinese patent 202011266740.1 (application date is 2020.11.12, applicant is West China Hospital of Sichuan University, publication number is CN 114480250 A, publication date is 2022.05.13) uses normal immune mice to construct an in situ primary gastric cancer animal model through genetic engineering, which takes 100 days, much longer than this application. Although the patent also has an in situ primary gastric cancer animal model that can be constructed in only 45 days, it requires the use of transgenic mice for preliminary experiments, and the cost of modeling is too high.

[0084] The above results confirm that the method of the present invention will not lead to the death of animals before tumor formation, the model construction cycle is short, the model can be completed in only 8 weeks, and the tumor formation rate is high; moreover, the growth and development of the obtained tumor is single and controllable, and can reproduce the complex microenvironment in the human body.

[0085] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for constructing an in situ primary model of gastric cancer in animals, It is characterized in that The experimental plasmid and SB transposase plasmid were mixed as solutes and injected into the gastric mucosal wall of animals with physiological saline as solvent.

2. The construction method according to claim 1, It is characterized in that Experimental plasmids include: AKT plasmid and NICD1 plasmid.

3. The construction method according to claim 1, It is characterized in that Gastric cancer is gastric adenocarcinoma.

4. The construction method according to claim 1, It is characterized in that The animals are mice.

5. The construction method according to claim 2, It is characterized in that The concentrations of AKT plasmid, NICD1 plasmid and SB transposase plasmid in the injection system were all 2.5 μg / mL.

6. The construction method according to claim 1, It is characterized in that The gastric mucosal wall is the gastric mucosal wall on the lesser curvature of the stomach.

7. The construction method according to claim 1, It is characterized in that The specific operation of injecting into the gastric mucosal wall of the animal is as follows: after the animal is anesthetized, the stomach is pulled outside the abdomen, and physiological saline containing the experimental plasmid and SB transposase plasmid is pushed into the gastric mucosal wall, and then the stomach is placed back into the abdominal cavity and the abdominal incision is closed.

8. An animal orthotopic gastric cancer model, It is characterized in that The animal gastric cancer in situ primary model is constructed using the method for constructing the animal gastric cancer in situ primary model according to any one of claims 1 to 7.

9. The model according to claim 8, It is characterized in that The animals are mice.

10. The model according to claim 8, It is characterized in that Gastric cancer is gastric adenocarcinoma.